AGIO

Agios Pharmaceuticals, Inc.

35.01 USD
+0.20 (+0.57%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Agios Pharmaceuticals, Inc. stock is up 46.67% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 February’s closed higher than January. In the last 9 Unusual Options Trades, there were 8 CALLs, 1 PUT. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Jan 20:54 19 Jan, 2024 22.50 CALL 330 1
25 Jan 20:11 21 Jun, 2024 22.50 CALL 200 22
26 Jan 16:20 17 May, 2024 25.00 CALL 240 1008
15 Feb 20:53 15 Mar, 2024 25.00 CALL 125 167
22 Feb 17:54 20 Dec, 2024 35.00 PUT 123 942
23 Feb 15:17 19 Apr, 2024 30.00 CALL 1000 3
23 Feb 15:22 15 Mar, 2024 20.00 CALL 25 0
23 Feb 15:53 15 Mar, 2024 20.00 CALL 25 0
27 Feb 19:38 19 Apr, 2024 40.00 CALL 400 1

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes. AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

  • JP Morgan
    Fri Feb 23, 12:33
    hold
    confirm
  • RBC Capital
    Fri Feb 16, 11:55
    buy
    confirm